Advanced search
Publication Cover
Journal of Pain & Palliative Care Pharmacotherapy Volume 26, 2012 - Issue 2
Submit an article Journal homepage
532
Views
2
CrossRef citations to date
0
Altmetric
LEGAL AND REGULATORY ISSUES IN PAIN AND PALLIATIVE CARE

Off-Label Prescribing of Medications for Pain: Maintaining Optimal Care at an Intersection of Law, Public Policy, and Ethics

James RubleJames H. Ruble, PharmD, JD, is Assistant Professor (Clinical) of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, Utah, USA.Correspondence[email protected]
Pages 146-152 | Published online: 19 Apr 2012

REFERENCES

  • Torres A. The use of Food and Drug Administration–approved medications for unlabeled (off-label) uses. Arch Dermatol. 1994;130:32–36.
  • Gillick MR. Controlling off-label medication use. Ann Intern Med. 2009;150:344–347.
  • Mello MM, Studdert DM, Brennan TA. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med. 2009;360:1557–1566.
  • 21 U.S.C. § 396 (2011).
  • Regulatory Information. Food and Drug Administration. “Off-Label” and investigational use of marketed drugs, biologics, and medical devices—information sheet guidance for institutional review boards and clinical investigators. Updated August 2011. Available at: http://www.fda.gov/Regulatory-Information/Guidances/ucm126486.htm. Accessed January 23, 2012.
  • Drug Safety Update. Medicines and Health Care products Regulatory Agency. Off-label or unlicensed use of medicines: prescribers’ responsibilities, updated April 2009. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafety-Update/CON087990. Accessed January 23, 2012.
  • Pharmaceuticals and Medical Devices Agency, Japan. Updated 2012. Available at: http://www.pmda.go.jp/english/index.html. Accessed January 23, 2012.
  • Off-label use of therapeutic products. Meeting Summary Report—Expert Advisory Committee on the Vigilance of Health Products (EAC-VHP)—May 31, June 1–2, 2011, updated August 2011. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/eacvhp-ccvrps/meet-reunion/jun-juin-11-eng.php#a25. Accessed January 23, 2012.
  • Therapeutic Goods Administration. Updated March 2011. http://www.tga.gov.au/. Accessed January 23, 2012.
  • Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Use of off-label medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185:544–548.
  • Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office based physicians. Arch Intern Med. 2006;166:1021–1026.
  • Chen DT, Wynia MK, Moloney RM, Alexander GC. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf. 2009;18:1094–1100.
  • Mack A. Examination of the evidence for off-label use of gabapentin. J Managed Care Pharm. 2003;9:559–568.
  • Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;(3):CD007938. DOI: 10.1002/14651858.CD007938.pub2.
  • Food, Drug and Cosmetic Act § 554. 21 USC §360aaa (1997).
  • Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med. 2011;8:e1000431. DOI: 10.1371/journal.pmed.1000431.
  • Cent. Hudson Gas & Elec. Corp. v. Publ. Serv. Comm'n, 447 U.S. 748 (1976).
  • Thompson v. Western States Medical Center, 535 U.S. 357 (2002).
  • Washington Legal Foundation v. Henney, 202 F.3d 331 (D.C. Cir. 2000).
  • Legal Backgrounder. Washington Legal Foundation. “Off-label” speech: uncertainty reigns for device and drug makers. Available at: http://www.wlf.org/upload/120205LBHall.pdf. Accessed February 6, 2012.
  • Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 6th ed. New York, Oxford University Press; 2009.
  • Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics. 2009;Fall:476–486.
  • Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course. Evidence and ethical off-label prescribing. Arch Intern Med. 2009;169:1745–1747.
  • Verhagen CCAHHVM, Niezink AGH, Engels YY, Hekster YYA, Doornebal JJ, Vissers KCP. Off-label use of drugs in pain medicine and palliative care: an assessment of its safe and legal prescription. Pain Pract. 2008;8:157–163.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.